Enveric Biosciences Inc

This advisory Say-on-Pay proposal asks shareholders to affirm, on a non-binding basis, the Board and Compensation Committee’s executive compensation decisions and disclosed pay practices for named executive officers. Management frames compensation as a mix of base salary, performance-based bonuses and equity-based awards designed to align executive incentives with both short- and long-term corporate objectives, to attract and retain talent, and to promote pay-for-performance. The Compensation Committee will consider the outcome when setting future pay but is not legally bound by it, making the vote primarily a governance feedback mechanism. The company states its philosophy emphasizes significant equity components and performance conditions; historical disclosures show sizable RSU grants and severance protections for named executives, which may be scrutinized by institutional investors. A FOR recommendation from the Board reflects its judgment that current pay structures and disclosure are appropriate given the Company’s stage, recent reverse split and financing needs, and the need to retain key management during critical development and financing periods. Critics could argue that large equity grants and change-in-control or severance provisions risk misaligning pay with realized shareholder returns, particularly for a small-cap biotech with volatile outcomes; proponents counter that competitive equity is necessary in the sector. The vote is non-binding, so a strong dissent signal would still be influential — the Board has committed to reviewing results and potentially adjusting compensation practices in response. Investors evaluating this proposal should weigh the disclosed pay mix, quantum of equity grants, vesting and performance conditions, and historical pay-versus-performance metrics to judge whether management incentives are aligned with shareholder value creation. The outcome is an important tone-setting governance signal but will not automatically change pay arrangements absent subsequent Board action.

The Reverse Stock Split proposal asks shareholders to grant the Board a time-limited, discretionary authority to combine issued and outstanding shares within a 1-for-5 to 1-for-15 range, with the exact ratio set by the Board if implemented. Management frames this as a toolbox item to help increase the per-share price (potentially attracting institutional investors and broker-dealers), cure Nasdaq minimum bid price deficiencies, and improve marketability and liquidity. The discrete range and Board discretion are intended to preserve flexibility to select an optimal ratio based on market conditions at execution; that flexibility can be commercially pragmatic but reduces shareholder control over the exact economic effect. The company previously received similar authorization at a December 2025 special meeting; this proposal would supersede and extend that authority. Key risks include the possibility that price appreciation is short-lived, potential decreased liquidity due to fewer outstanding shares, odd-lot issues for small holders, and potential negative signaling to the market about underlying fundamentals. The Board emphasizes that no split will occur unless it deems it in shareholders’ best interests; however, because the Board also gains operational and financing flexibility post-split (e.g., more authorized but unissued shares effectively available), investors should assess whether the Board might use the split opportunistically. From a governance and activist-investor perspective, the proposal is routine but material—approval is common for small-cap issuers facing listing pressure, yet it warrants scrutiny of pro forma capitalization and post-split dilution scenarios. Analysts evaluating the proposal should weigh the company’s trading history, Nasdaq compliance risk, fundraising needs, and whether alternative measures (reverse split plus other strategic steps) would better protect long-term shareholder value. Overall, the Board’s recommendation is driven by listing preservation and capital-market access considerations; shareholders should consider both the utility and the potential adverse market/liquidity consequences.

This proposal asks shareholders to reauthorize a previously approved increase in authorized common shares — from 100 million to 5 billion — granting the Board discretion to effect the amendment within 12 months. Management frames the extension as a pragmatic step to preserve corporate flexibility for capital raises, equity compensation, strategic transactions (M&A, business combinations), or even a ‘‘digital asset treasury’’ as noted in the filing. The authority itself does not immediately dilute shareholders but materially expands the potential share pool the Board may use, placing importance on Board judgment and governance safeguards around opportunistic issuance. The key governance concern is the breadth of discretion: once effective, the Board can issue large quantities of stock without further shareholder approval, which could significantly dilute existing holders or enable defensive or transformational transactions. Supporters will argue that a small-cap biotech needs rapid access to capital and that the enlarged authorized pool avoids the delay and cost of convening a shareholder meeting at short notice. Opponents and governance-focused investors will request clarity on contemplated uses, pre-emptive issuance policies, and safeguards (e.g., board approval thresholds, use restrictions) to protect long-term holders. The prior December 2025 approval underscores that this is an administrative extension rather than a new strategic shift, but the scale (50x increase) is large and thus deserves scrutiny. Analysts should examine recent financing plans, outstandings (warrants, RSUs), and whether there are commitments or contingent transactions that make the authorization necessary. In sum, while providing tactical flexibility, the proposal raises potential dilution and governance trade-offs that sophisticated investors should monitor closely if they vote FOR.

The Adjournment Proposal seeks stockholder approval to empower proxies to adjourn or postpone the Annual Meeting if there are insufficient votes to approve any substantive items or a quorum is not established. Management argues this is a practical procedural measure to permit additional solicitations and avoid having to reconvene a separate meeting, which would be costly and slow. The proposal is standard in contested vote or low-turnout scenarios and reduces execution risk for governance and transaction timing, but it also enables the Company to continue soliciting in case of initial vote shortfalls, potentially prolonging the solicitation period. From a governance perspective, investors should consider that adjournment power can be used defensively to buy time to obtain votes, which is typical, but shareholders might weigh whether management is using it to overcome legitimate opposition without addressing underlying concerns. The Board recommends FOR, noting the proposal is only to allow additional time to secure votes or a quorum rather than to change substantive matters. Sophisticated investors should track post-meeting disclosures if adjournments are used and assess whether management’s subsequent solicitations materially change the original disclosures or proposals.